CN102007223B - 用于胃癌的诊断、预后和治疗的基于微rna的方法和组合物 - Google Patents

用于胃癌的诊断、预后和治疗的基于微rna的方法和组合物 Download PDF

Info

Publication number
CN102007223B
CN102007223B CN200980112966.1A CN200980112966A CN102007223B CN 102007223 B CN102007223 B CN 102007223B CN 200980112966 A CN200980112966 A CN 200980112966A CN 102007223 B CN102007223 B CN 102007223B
Authority
CN
China
Prior art keywords
mir
expression
cells
marker
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980112966.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102007223A (zh
Inventor
C·M·克罗斯
F·派特罗卡
A·维克驰欧尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Publication of CN102007223A publication Critical patent/CN102007223A/zh
Application granted granted Critical
Publication of CN102007223B publication Critical patent/CN102007223B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/205—Aptamer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200980112966.1A 2008-02-28 2009-02-27 用于胃癌的诊断、预后和治疗的基于微rna的方法和组合物 Expired - Fee Related CN102007223B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6744508P 2008-02-28 2008-02-28
US61/067,445 2008-02-28
PCT/US2009/035458 WO2009108853A1 (en) 2008-02-28 2009-02-27 MicroRNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF GASTRIC CANCER

Publications (2)

Publication Number Publication Date
CN102007223A CN102007223A (zh) 2011-04-06
CN102007223B true CN102007223B (zh) 2014-06-18

Family

ID=41016479

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980112966.1A Expired - Fee Related CN102007223B (zh) 2008-02-28 2009-02-27 用于胃癌的诊断、预后和治疗的基于微rna的方法和组合物

Country Status (7)

Country Link
US (1) US20110034538A1 (enExample)
EP (2) EP3064584A3 (enExample)
JP (1) JP5662166B2 (enExample)
CN (1) CN102007223B (enExample)
AU (1) AU2009219190A1 (enExample)
CA (1) CA2716906A1 (enExample)
WO (1) WO2009108853A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103866018B (zh) 2005-08-01 2016-05-25 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
CN103028120B (zh) 2005-09-12 2015-08-12 俄亥俄州立大学研究基金会 用于诊断或治疗bcl2相关癌症的组合物和方法
EP2487260B1 (en) 2006-01-05 2015-07-08 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007081720A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
ES2524018T3 (es) 2006-01-05 2014-12-03 The Ohio State University Research Foundation Anomalías de la expresión de microARN en tumores pancreáticos endocrinos y acinares
EP2369012A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Micro-RNA fingerprints during human megakaryocytopoiesis
CA2657030A1 (en) 2006-07-13 2008-01-17 The Ohio State University Research Foundation, An Instrumentality Of The State Of Ohio Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
US8071292B2 (en) 2006-09-19 2011-12-06 The Ohio State University Research Foundation Leukemia diagnostic methods
JP5501766B2 (ja) 2006-11-01 2014-05-28 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 肝細胞癌における生存および転移を予測するためのマイクロｒｎａ発現サイン
US8034560B2 (en) 2007-01-31 2011-10-11 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML)
CA2690144A1 (en) 2007-06-08 2008-12-18 The Government Of The United States Of America As Represented By The Sec Retary Of Department Of Health And Human Services Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
ES2496172T3 (es) 2007-07-31 2014-09-18 The Ohio State University Research Foundation Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B
AU2008283997B2 (en) 2007-08-03 2014-04-10 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
CN101836112A (zh) 2007-08-22 2010-09-15 俄亥俄州立大学研究基金会 用于在人急性白血病中诱导epha7和erk磷酸化的脱调节的方法和组合物
CA2703707A1 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
AU2009257410B2 (en) 2008-06-11 2014-03-06 Fudan University Use of miR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
JP5960060B2 (ja) 2009-11-23 2016-08-02 ジ・オハイオ・ステート・ユニバーシティ 腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法
WO2012010584A1 (en) * 2010-07-20 2012-01-26 Febit Holding Gmbh Complex mirna sets as novel biomarkers for gastric cancer
WO2012065049A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
SG182016A1 (en) * 2010-12-14 2012-07-30 Univ Singapore Method of detecting resistance to cancer therapy
US8664192B2 (en) 2011-03-07 2014-03-04 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
JP6211511B2 (ja) * 2011-04-18 2017-10-11 ディアミール, エルエルシーDiamir, Llc ｍｉＲＮＡに基づくユニバーサルスクリーニングテスト（ＵＳＴ）
US8703425B2 (en) * 2011-09-12 2014-04-22 The Chinese University Of Hong Kong Biomarker for gastric cancer
GB201117482D0 (en) * 2011-10-11 2011-11-23 Univ Dundee Targetiing of miRNA precursors
EP2766500A4 (en) 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
CN104619353A (zh) 2011-12-13 2015-05-13 俄亥俄州国家创新基金会 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移
JP2015511121A (ja) 2012-01-20 2015-04-16 ジ・オハイオ・ステート・ユニバーシティ 浸潤性および予後に関する乳がんバイオマーカーシグネチャー
US9845465B2 (en) 2012-08-15 2017-12-19 University Of Virginia Patent Foundation Compositions and methods for treating peripheral arterial disease
JPWO2014097875A1 (ja) * 2012-12-20 2017-01-12 国立大学法人鳥取大学 新規の脱分化誘導方法を用いた多能性幹細胞化
CN104013975A (zh) * 2014-06-16 2014-09-03 山东大学 Fbxo31基因及其相关产物在制备胃癌治疗药物中的应用
CN106460068B (zh) * 2014-06-16 2024-08-23 东丽株式会社 胃癌的检测试剂盒或装置以及检测方法
EP4137586A1 (en) * 2014-08-07 2023-02-22 Agency for Science, Technology and Research Microrna biomarker for the diagnosis of gastric cancer
CN104293923A (zh) * 2014-09-19 2015-01-21 浙江大学 荧光定量PCR检测组织中miR-100含量的试剂盒及其应用
CN106591428B (zh) * 2016-09-23 2021-06-11 宁波大学 一种胃癌新型分子标记物hsa_circ_0001017的检测及应用
CN106636334B (zh) * 2016-10-09 2020-07-03 山东大学 microRNA标志物组及其在制备检测胃癌淋巴结转移试剂盒中的应用
CN106755513B (zh) * 2017-02-08 2018-10-19 泰山医学院 一种胃癌的lncRNA标志物
RU2019134769A (ru) * 2017-03-31 2021-04-30 Дзе Кьюрейторз Оф Дзе Юниверсити Оф Миссури Композиции для лечения резистентных к лекарственным средствам опухолей и способы их применения
CN107217055B (zh) * 2017-06-26 2019-01-18 生工生物工程（上海）股份有限公司 一种癌症诊断芯片及其试剂盒
CN107641653B (zh) * 2017-10-20 2021-02-19 南方医科大学南方医院 Macc1-as1探针在制备用于预测胃癌临床预后的诊断试剂中的应用
CN108546757B (zh) * 2018-03-05 2021-09-07 上海长海医院 Zfpm2-as1在制备胃癌诊断试剂或试剂盒中的应用
KR102100124B1 (ko) * 2018-08-31 2020-05-15 한국표준과학연구원 질량 분석법을 이용한 생체 분자의 고감도 및 고특이적 검출 방법
JP7512285B2 (ja) * 2018-12-19 2024-07-08 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ マイクロｒｎａを用いた胃癌の診断方法
CN117683885A (zh) * 2019-04-30 2024-03-12 觅瑞实验室私人有限公司 一种检测胃癌的miRNA标志物组合及试剂盒
CN111471764B (zh) * 2019-12-27 2023-09-15 陈锦飞 一种用于筛查或辅助诊断胃癌的生物标志物组合及其试剂盒和应用
CN111139299B (zh) * 2020-01-08 2021-12-17 浙江大学 Josd2蛋白在制备治疗恶性肿瘤药物中的应用
CN111471683B (zh) * 2020-04-15 2021-09-07 湖南省科域生物医药科技有限公司 miR-93-5p作为诊断和治疗胃癌标志物的应用
CN114678121B (zh) * 2022-05-30 2022-09-09 上海芯超生物科技有限公司 一种hp球形变诊断模型的构建方法及系统

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012187A1 (en) * 1994-10-13 1996-04-25 Horus Therapeutics, Inc. Computer assisted methods for diagnosing diseases
US6303323B1 (en) * 1997-10-21 2001-10-16 Cancer Research Campaign Technology Limited Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies
US6891031B2 (en) * 2000-02-18 2005-05-10 The Regents Of The University Of California Coordinate cytokine regulatory sequences
AU2002360377A1 (en) * 2001-11-09 2003-05-19 The Ohio State University Research Foundation Baalc expression as a diagnostic marker for acute leukemia
WO2003069853A1 (en) * 2002-02-12 2003-08-21 Nokia Corporation Method for controlling data transmission, and data transmission system
WO2004071464A2 (en) * 2003-02-12 2004-08-26 Johns Hopkins University School Of Medicine Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells
US20050069918A1 (en) * 2003-05-29 2005-03-31 Francois Claret JAB1 as a prognostic marker and a therapeutic target for human cancer
US8106180B2 (en) * 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US20050164252A1 (en) * 2003-12-04 2005-07-28 Yeung Wah Hin A. Methods using non-genic sequences for the detection, modification and treatment of any disease or improvement of functions of a cell
US20060134639A1 (en) * 2004-04-06 2006-06-22 Huffel Christophe V Method for the determination of cellular transcriptional regulation
JP2007533324A (ja) * 2004-04-20 2007-11-22 ゲナコ・バイオメデイカル・プロダクツ・インコーポレイテツド ｎｃＲＮＡを検出する方法
EP2290071B1 (en) * 2004-05-28 2014-12-31 Asuragen, Inc. Methods and compositions involving microRNA
KR20070058441A (ko) * 2004-07-01 2007-06-08 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 면역억제성 엑소솜
US7893034B2 (en) * 2004-09-02 2011-02-22 Yale University Regulation of oncogenes by microRNAs
US7642348B2 (en) * 2004-10-04 2010-01-05 Rosetta Genomics Ltd Prostate cancer-related nucleic acids
US7571055B2 (en) * 2004-10-13 2009-08-04 Regents Of The University Of Minnesota Systemic lupus erythematosus
EP2314688B1 (en) * 2004-11-12 2014-07-16 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US8071306B2 (en) * 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
CA2597767A1 (en) * 2005-02-11 2006-08-17 Wisconsin Alumni Research Foundation Mir-155 assay
US20070213292A1 (en) * 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070092882A1 (en) * 2005-10-21 2007-04-26 Hui Wang Analysis of microRNA
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007081720A2 (en) * 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
EP2487260B1 (en) * 2006-01-05 2015-07-08 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis and treatment of solid cancers
ES2524018T3 (es) * 2006-01-05 2014-12-03 The Ohio State University Research Foundation Anomalías de la expresión de microARN en tumores pancreáticos endocrinos y acinares
KR101407707B1 (ko) * 2006-04-03 2014-06-19 산타리스 팔마 에이/에스 Ａｎｔｉ-ｍｉｒｎａ 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물
CA2657030A1 (en) * 2006-07-13 2008-01-17 The Ohio State University Research Foundation, An Instrumentality Of The State Of Ohio Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
JP2010510964A (ja) * 2006-09-19 2010-04-08 アシュラジェン インコーポレイテッド 治療的介入の標的としての、ｍｉＲ−１５、ｍｉＲ−２６、ｍｉＲ−３１、ｍｉＲ−１４５、ｍｉＲ−１４７、ｍｉＲ−１８８、ｍｉＲ−２１５、ｍｉＲ−２１６、ｍｉＲ−３３１、ｍｍｕ−ｍｉＲ−２９２−３ｐによって調節される遺伝子および経路
CA2671294A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
ATE553196T1 (de) * 2007-02-27 2012-04-15 Rosetta Genomics Ltd Zusammensetzung und verfahren zur modulation von zellproliferation und zelltod
EP2126584B1 (en) * 2007-03-16 2012-12-19 CovalX AG Direct mass spectrometric analysis of drug candidates targeting protein complexes
CA2676113C (en) * 2007-07-25 2014-07-08 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker
CN101836112A (zh) * 2007-08-22 2010-09-15 俄亥俄州立大学研究基金会 用于在人急性白血病中诱导epha7和erk磷酸化的脱调节的方法和组合物
US20090239818A1 (en) * 2007-09-07 2009-09-24 Cheng Jin Q Effective treatment of ovarian cancer using triciribine and related compounds
WO2009044899A1 (ja) * 2007-10-03 2009-04-09 Kyowa Hakko Kirin Co., Ltd. 細胞の増殖を制御する核酸
US8288356B2 (en) * 2007-10-04 2012-10-16 Santaris Pharma A/S MicroRNAs
CN101980712B (zh) * 2007-10-29 2015-02-18 雷古拉斯治疗公司 用于肝癌治疗的靶向微小rna
EP2604704B1 (en) * 2008-02-01 2018-10-03 The General Hospital Corporation Use of microvesicles in diagnosis and prognosis of brain tumor
WO2009108860A2 (en) * 2008-02-28 2009-09-03 The Ohio University Rasearch Foundation Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
JP2011515078A (ja) * 2008-03-01 2011-05-19 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ＳＰＡＲＣ特異的ｍｉＲＮＡを使用する、治療、診断、及び拮抗物質発見方法
WO2009111643A2 (en) * 2008-03-06 2009-09-11 Asuragen, Inc. Microrna markers for recurrence of colorectal cancer
US20110107440A1 (en) * 2008-06-04 2011-05-05 Andor Pivarcsi Skin cancer associated micrornas
US20100021734A1 (en) * 2008-07-22 2010-01-28 Covalent Materials Corporation Ceramic particles and producing method thereof
KR101031305B1 (ko) * 2008-07-23 2011-04-29 국립암센터 마이크로ｒｎａ-21 저해제를 포함하는 방사선 민감성증진용 조성물
WO2010056737A2 (en) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
US20110275534A1 (en) * 2008-12-05 2011-11-10 The Ohio State University MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Ovarian Cancer Using a Real-Time PCR Platform

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
《 MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression》;Ivanovska I, et al;《Mol Cell Bio》;20080122(第7期);2167-74 *
《 Molecular Evolution of a microRNA Claster》;Tanzer A, et al.;《J Mol Biol》;20040528;第339卷(第2期);327-335 *
《Processing of intronic miroRNAs》;Kim YK et al;《EMBO》;20070125;第26卷(第3期);第777页左栏第1-2行、图3B *
Ivanovska I, et al.《 MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression》.《Mol Cell Bio》.2008,(第7期),2167-74.
Kim YK et al.《Processing of intronic miroRNAs》.《EMBO》.2007,第26卷(第3期),第777页左栏第1-2行、图3B.
Tanzer A, et al..《 Molecular Evolution of a microRNA Claster》.《J Mol Biol》.2004,第339卷(第2期),摘要.

Also Published As

Publication number Publication date
EP3064584A3 (en) 2016-12-07
WO2009108853A1 (en) 2009-09-03
JP2011516032A (ja) 2011-05-26
CN102007223A (zh) 2011-04-06
EP2257647A4 (en) 2011-08-03
US20110034538A1 (en) 2011-02-10
CA2716906A1 (en) 2009-09-03
EP2257647B1 (en) 2016-09-14
EP2257647A1 (en) 2010-12-08
AU2009219190A1 (en) 2009-09-03
JP5662166B2 (ja) 2015-01-28
EP3064584A2 (en) 2016-09-07

Similar Documents

Publication Publication Date Title
CN102007223B (zh) 用于胃癌的诊断、预后和治疗的基于微rna的方法和组合物
CN102027129B (zh) 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物
AU2009322907B2 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
Del Vescovo et al. MicroRNAs as lung cancer biomarkers
AU2009219203B2 (en) MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia (AML) and uses thereof
JP2010535782A (ja) Ｄｎｍｔ３ａ及びｄｎｍｔ３ｂを標的にすることによるメチル化を元に戻す方法
JP2010535473A (ja) ｎｃＲＮＡをコードする超保存領域
CN102015027A (zh) 与人慢性淋巴细胞性白血病(ccl)相关的微rna特征和其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140618

Termination date: 20180227